A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment (NCT04576156)
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients With Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor
🩺 Plain-English Summary (8th-Grade Level)
The purpose of the study is to evaluate the overall survival of participants treated with imetelstat compared to best available therapy with intermediate-2 or high-risk Myelofibrosis (MF) who are relapsed/refractory (R/R) to Janus Kinase (JAK)-Inhibitor treatment.
Who can join: Review the eligibility criteria below.
Location: University of California-San Diego/Moores UCSD Cancer Center — La Jolla, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (144 Sites)
Showing the first 25 of 144 sites.
- University of California-San Diego/Moores UCSD Cancer Center — La Jolla, California
- UCLA David Geffen School of Medicine — Los Angeles, California
- Smilow Cancer Center at YNHH — New Haven, Connecticut
- BRCR Medical Center Inc — Plantation, Florida
- University of South Florida — Tampa, Florida
- Norton Cancer Institute — Louisville, Kentucky
- Icahn School of Medicine at Mount Sinai — New York, New York
- Duke University Medical Center — Durham, North Carolina
- Gabrail Cancer Center — Canton, Ohio
- Prairie Lakes Health Care System, Inc. — Watertown, South Dakota
- The University of Texas MD — Houston, Texas
- Northwest Medical Specialties PLLC — Seattle, Washington
- Hospital Aleman — Ciudad de Buenos Aires, Buenos Aires
- Sanatorio de la Mujer — Rosario, Santa Fe Province
- Sanatorio Allende — Córdoba,
- Royal North Shore Hospital — St Leonards, New South Wales
- Royal Brisbane and Women's Hospital — Herston, Queensland
- Royal Hobart Hospital — Hobart, Tasmania
- Epworth Healthcare — Richmond, Victoria
- Krankenhaus Hietzing mit Neurologischem Zentrum Rosenhügel — Wein, Burgenland
- Krankenhaus der Elisabethinen — Linz, Upper Austria
- Kepler Universitätsklinikum Gm — Linz, Upper Austria
- Klinikum Wels-Grieskirchen GmbH — Wels, Upper Austria
- AZ Klina — Antwerp, Antwerpen
- UZ Antwerpen — Edegem, Antwerpen
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Myelofibrosis
- Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms — Birmingham, Alabama
- Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis — Calgary, Alberta
- Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis — Birmingham, Alabama
- Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) — Birmingham, Alabama
- A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis — Pasadena, California
- A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis) — Newport Beach, California
Explore by condition: All Myelofibrosis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.